Studies related to Rhonchi and Pelargonium sidoides

Pelargonium Sidoides Preparation (EPs 7630) In The Treatment Of Acute Bronchitis In Adults And Children

Effect Decrease
Trial Design Double blind
Trial Length 1-2 Weeks
Number of Subjects 2023
Gender Both Genders
Age Range 0-1, 1-6, 7-12, 13-17, 18-29, 30-44, 45-64, 65+
Notes for this study:
Two weeks supplementation of EPs7630 to persons of all ages (30 drops thrice daily for adults, but 20 drops thrice daily for those between 6-12 and 10 drops thrice daily for those younger than 6) was able to significantly reduce overall symptoms as assessed by the BSS by around 86% with 68% of the sample reporting more than a 5 point reduction.

Most other comorbidities such as fever, fatigue, and headache were reduced in the range of 80-94.6%. Rhonchi (93.1% remission) chest pain during cough (94.1%), and shortness of breath (93.2%), but cough was only abolished in 56.2% of persons.

Efficacy And Safety Of An Extract Of Pelargonium Sidoides (EPs 7630) In Adults With Acute Bronchitis. A Randomised, Double-blind, Placebo-controlled Trial

Effect Decrease
Trial Design Double blind
Trial Length 1-7 Days
Number of Subjects 468
Gender Both Genders
Age Range 30-44, 45-64
Body Types Average
Notes for this study:
Thirty drops (4.5mL) of Eps7630 thrice daily for a week in adults with acute bronchitis around the time of meals was associated with a greater decrease of overall symptoms as assessed by the BSS rating scale (70% reduction in symptoms) relative to placebo (40%) with symptom reduction occurring in about three days time.

EPs7630 was also more effective at causing an overall rating of less than three on the 10 point rating scale (64.4% relative to 37.9%) and at inducing a 7 point reduction within the week (43.3% relative to 23% in placebo).

After 7 days, there was abolishment of rhonchi (77.1%), coughing (83.8%) fatigue (65.1%), headache (75-81.7%), and fever (96.9%) in treatment, all more than placebo.

Treatment Of Acute Bronchitis In Adults With A Pelargonium Sidoides Preparation (EPs 7630): A Randomized, Double-blind, Placebo-controlled Trial

Effect Decrease
Trial Design Double blind
Trial Length 1-7 Days
Number of Subjects 107
Gender Both Genders
Age Range 18-29, 30-44, 45-64
Body Types Average
Notes for this study:
30 drops (4.5mL) of EPs7630 thrice daily for a week in adults with acute bronchitis was associated with significant reductions in symptoms as assessed by the BSS rating scale. There was also a greater change of a 5 point reduction in the treatment group (90.6%) rather than placebo (51.7%) and reported rapid recovery (90.6% relative to 41.7%); there were significantly more remissions of cough (31.3%), rhonchi (91%)

Treatment Of Acute Bronchitis With A Liquid Herbal Drug Preparation From Pelargonium Sidoides (EPs 7630): A Randomised, Double-blind, Placebo-controlled, Multicentre Study

Effect Decrease
Trial Design Double blind
Trial Length 1-7 Days
Number of Subjects 217
Gender Both Genders
Age Range 18-29, 30-44, 45-64
Body Types Average
Notes for this study:
In adult patients with acute bronchitis given 30 drops of EPs7630 thrice daily for a period of one week, symptoms of acute bronchitis (BSS) was able to increase complete remission on day seven to 45.4% of the treatment group (over 6.4% of the placebo) as assessed by physicians, and 89.8% and 65.1% self-reported complete or major recovery (more 'complete' recovery in treatment). Most marked improvement was in cough, where only 11.9% of placebo reported complete recovery while 51.9% of treatment did after seven days.

EPs 7630 Improves Acute Bronchitic Symptoms And Shortens Time To Remission. Results Of A Randomised, Double-blind, Placebo-controlled, Multicentre Trial

Effect Decrease
Trial Design Double blind
Trial Length 1-7 Days
Number of Subjects 217
Gender Both Genders
Age Range 18-29, 30-44, 45-64
Body Types Average
Notes for this study:
In adult outpatients with acute bronchitis given the standard 30 drops of EPs7630 thrice daily for a period of seven days, there were significantly improved symptoms on all parameters of the BSS and secondary outcome variables with particular improvement in fatigue and coughs; days off from work was reduced secondary to helping cure acute bronchitis.